Jacob Kelly, MD
Advanced Heart Failure and Transplant Cardiology · Anchorage, AKNPI 1851551949
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,460 of the $43,028 with a category attached, or 82.4%. Novartis accounts for 79.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $36,373 and has fallen 97.9% since, to $756 in 2025.
Across 164 payments — averaging $262.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$34K
- Actelion Pharmaceuticals US, Inc.$6K
- Abbott$765
- E.r. Squibb & Sons, L.L.C.$543
- Alnylam Pharmaceuticals Inc.$391
- Impulse Dynamics (USA) Inc.$282
- plus $1K from 18 others
Across 42 payments — averaging $14,515 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$419K
- Amgen$171K
- Eli Lilly$16K
- Akcea Therapeutics, Inc.$4K
What the payments were for
- Speaking & faculty fees$35,46082%
- Travel & lodging$2,4036%
- Food & beverage$5,14512%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $34,008 |
| Actelion Pharmaceuticals US, Inc. | 9 | $5,568 |
| Abbott | 15 | $765 |
| E.r. Squibb & Sons, L.L.C. | 25 | $543 |
| Alnylam Pharmaceuticals Inc. | 12 | $391 |
| Impulse Dynamics (USA) Inc. | 2 | $282 |
| Bayer | 3 | $233 |
| Pfizer | 7 | $135 |
| United Therapeutics Corporation | 2 | $127 |
| Abiomed | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| Cleerly, Inc. | 2 | $121 |
| Medtronic | 1 | $106 |
| Boston Scientific | 3 | $100 |
| Lilly USA, LLC | 1 | $82 |
| Merck | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $55 |
| Amgen | 3 | $41 |
| Boehringer Ingelheim | 2 | $41 |
| Johnson & Johnson | 3 | $38 |
| Chiesi USA, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few advanced heart failure and transplant cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 370 | $419,698 |
| EliquisApixaban | 266 | $393,008 |
| JardianceEmpagliflozin | 239 | $282,285 |
| VyndamaxTafamidis | 13 | $266,514 |
| FarxigaDapagliflozin Propanediol | 60 | $92,873 |
| XareltoRivaroxaban | 66 | $78,245 |
| Repatha SureclickEvolocumab | 30 | $35,123 |
| WegovySemaglutide | 14 | $20,243 |
| OzempicSemaglutide | 18 | $18,990 |
| Eplerenone | 70 | $10,315 |
| Metoprolol Succinate | 398 | $9,362 |
| Spironolactone | 523 | $6,000 |
| Sildenafil Citrate | 13 | $4,631 |
| Atorvastatin Calcium | 270 | $4,098 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $3,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $135 | $659,521279 claims |
| NovartisEntresto | $34,008 | $419,698370 claims |
| Boehringer IngelheimJardiance, Pradaxa | $41 | $284,250276 claims |
| AstraZenecaFarxiga | $19 | $92,87360 claims |
| Johnson & JohnsonXarelto | $38 | $78,24566 claims |
| Novo NordiskWegovy, Ozempic | $125 | $39,23332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.